Edition:
United Kingdom

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

190.00SEK
21 Jun 2018
Change (% chg)

-1.55kr (-0.81%)
Prev Close
191.55kr
Open
192.30kr
Day's High
192.60kr
Day's Low
189.30kr
Volume
454,416
Avg. Vol
823,744
52-wk High
194.75kr
52-wk Low
107.40kr

Chart for

About

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers... (more)

Overall

Beta: 1.57
Market Cap(Mil.): kr34,172.46
Shares Outstanding(Mil.): 272.51
Dividend: --
Yield (%): --

Financials

  SOBIV.ST Industry Sector
P/E (TTM): 46.65 30.95 32.74
EPS (TTM): 2.69 -- --
ROI: 8.68 14.84 14.38
ROE: 12.91 16.34 16.08

BRIEF-Sobi appoints Henrik Stenqvist as new CFO

* HENRIK STENQVIST IS JOINING SOBI AS NEW CHIEF FINANCIAL OFFICER

26 Feb 2018

BRIEF-Swedish Orphan Biovitrum says receives positive opinion from CHMP on Anakira

* The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Anakinra for the treatment of Still’s disease.

23 Feb 2018

UPDATE 1-‍Sobi Q4 tops forecast but 2018 outlook below market expectations​

Feb 22 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Thursday a bigger fourth-quarter profit jump than expected but guided for slightly slower profit growth in 2018 than estimated by analysts.

22 Feb 2018

BRIEF-‍Sobi Q4 core profit beats expectations ​

* SAYS ‍SOBI EXPECTS TOTAL REVENUES FOR FULL-YEAR TO BE IN RANGE OF SEK 7,500 - 7,700 M.​

22 Feb 2018

Earnings vs. Estimates